Provided by Tiger Fintech (Singapore) Pte. Ltd.

Capricor Therapeutics

11.92
+0.67005.96%
Post-market: 11.950.0300+0.25%17:30 EDT
Volume:2.07M
Turnover:24.21M
Market Cap:544.46M
PE:-10.37
High:12.17
Open:11.15
Low:11.15
Close:11.25
Loading ...

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
18 Mar

Capricor Therapeutics announces long-term data from HOPE-2 OLE study

TIPRANKS
·
17 Mar

Capricor Therapeutics Inc: Deramiocel Was Well Tolerated With No New Safety Signals Identified

THOMSON REUTERS
·
17 Mar

Capricor Therapeutics Announces Positive Data Demonstrating Long-Term Efficacy of Deramiocel for the Treatment of Duchenne Muscular Dystrophy

GlobeNewswire
·
17 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
14 Mar

Capricor Therapeutics to Present Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Update on March 19

GlobeNewswire
·
11 Mar

Capricor Therapeutics' Biologics License Application for Deramiocel Accepted by FDA

MT Newswires Live
·
10 Mar

Capricor Therapeutics Inc - FDA Grants Priority Review for Deramiocel With Pdufa Date August 31, 2025

THOMSON REUTERS
·
10 Mar

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

THOMSON REUTERS
·
10 Mar

FDA Accepts Biologics License Application for Duchenne Muscular Dystrophy Cardiomyopathy Treatment

PR Newswire
·
10 Mar

Capricor Therapeutics Inc expected to post a loss of 26 cents a share - Earnings Preview

Reuters
·
07 Mar

Capricor Therapeutics, Inc. (CAPR): A Bull Case Theory

Insider Monkey
·
07 Mar

Capricor Therapeutics options imply 7.5% move in share price post-earnings

TIPRANKS
·
06 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
05 Mar

BUZZ-U.S. STOCKS ON THE MOVE-Okta, Natgas companies, UnitedHealth

Reuters
·
05 Mar

Capricor Therapeutics Price Target Maintained With a $77.00/Share by HC Wainwright & Co.

Dow Jones
·
05 Mar

Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition

Benzinga
·
05 Mar

Capricor Therapeutics: Promising Developments and Strategic Positioning Drive Buy Rating

TIPRANKS
·
04 Mar

Capricor Therapeutics Shares Rise on FDA Priority Review

Dow Jones
·
04 Mar

Capricor Therapeutics Shares up 10.1% After FDA Grants Priority Review to Co's Therapy for a Muscle-Wasting Related Heart Condition

THOMSON REUTERS
·
04 Mar